Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-09-03

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 3404

Registration Number: NCT01194401

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab SC
Drug: tocilizumab IV
Drug: placebo to tocilizumab IV
Drug: placebo to tocilizumab SC
Drug: Disease-modifying antirheumatic drugs (DMARDs)

First Posted Date: 2010-09-03

Last Posted Date: 2016-06-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1262

Registration Number: NCT01194414

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis, Primary Progressive

Interventions: Drug: Ocrelizumab
Other: Placebo

First Posted Date: 2010-09-03

Last Posted Date: 2024-01-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 735

Registration Number: NCT01194570

Locations: 🇺🇸
Maxine Mesinger MS Clinic/Baylor College of Medicine; Neurology, Houston, Texas, United States
🇺🇸
Swedish Neuroscience Institute; Multiple Sclerosis Center, Seattle, Washington, United States
🇺🇸
MidAmerica Neuroscience Institute, Prairie Village, Kansas, United States

and more 181 locations

A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)

Phase 2

Completed

Conditions: Kidney Disease, Chronic

Interventions: Drug: Placebo
Drug: Methoxy polyethylene glycol-epoetin beta

First Posted Date: 2010-09-02

Last Posted Date: 2017-05-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 241

Registration Number: NCT01194154

Locations: 🇩🇪
Klinikum d.Universität München Campus Großhadern, München, Germany
🇩🇪
Nierenzentrum Bogenhausen/Perlach; Praxis für Nierenheilkunde, München-Bogenhausen, Germany
🇩🇪
Charité - Klinikum Mitte; Medizinische Klinik Für Nephrologie, Berlin, Germany

and more 30 locations

An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

First Posted Date: 2010-09-02

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 289

Registration Number: NCT01194050

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Bitopertin
Drug: Antipsychotics

First Posted Date: 2010-09-01

Last Posted Date: 2017-02-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 625

Registration Number: NCT01192880

Locations: 🇺🇸
Synergy Clinical Research of Escondido, Escondido, California, United States
🇺🇸
Excell Research, Oceanside, California, United States
🇺🇸
Behavioral Clinical Research Inc., Lauderhill, Florida, United States

and more 100 locations

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: RO4917838
Drug: Placebo
Drug: Antipshychotics (Standard of Care)

First Posted Date: 2010-09-01

Last Posted Date: 2017-06-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 629

Registration Number: NCT01192867

Locations: 🇺🇸
Family Psychiatry of the Woodlands P.A., The Woodlands, Texas, United States
🇺🇸
CNRI - Los Angeles, LLC, Pico Rivera, California, United States
🇺🇸
Pillar Clinical Research LLC, Dallas, Texas, United States

and more 119 locations

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: bitopertin [RO4917838]
Drug: Placebo

First Posted Date: 2010-09-01

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 624

Registration Number: NCT01192906

A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy

Phase 4

Completed

Conditions: Anemia

Interventions: Drug: Methoxy polyethylene glycol-epoetin beta [Mircera]

First Posted Date: 2010-08-31

Last Posted Date: 2018-07-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 102

Registration Number: NCT01191983

Locations: 🇮🇳
Osmania General Hospital; Department of Nephrology, Hyderabad, Andhra Pradesh, India
🇮🇳
North Delhi Diabetes Centre, Delhi, India
🇮🇳
MAX Balaji Hospital, Delhi, India

and more 11 locations

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: placebo
Drug: aleglitazar
Drug: ibuprofen

First Posted Date: 2010-08-25

Last Posted Date: 2012-05-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 44

Registration Number: NCT01188317

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy